For an emerging pharma company approaching its first launch, the traditional choices can seem limiting: sell or license the asset to a larger company, or commit substantial capital to building a commercial organization from scratch. At the Indegene Digital Summit 2026, Shane J. Schaffer, Chairman and CEO of Cingulate Therapeutics, described a third model that aims to retain ownership and strategic control while accessing established commercial capabilities through partners. The discussion offered a different way to think about pharma go to market decisions when capital, speed, and execution quality all matter at once.
Break the Build, Sell, or License Trade-Off
The decision facing Cingulate combined both value and risk. Licensing or selling the asset would transfer a significant share of its future economics, while building a complete commercial organization would require substantial capital, additional headcount, and a large fixed cost base before launch performance was known. For an emerging company, either path can materially change the risk profile of the asset and the organization around it.
Cingulate instead chose to retain the asset and assemble the capabilities needed for commercialization through strategic partners. That creates a pharma commercialization strategy in which the company owns the asset, the leadership, and the key decisions without owning every executional capability. The model is intended to preserve value while reducing the need to replicate the full infrastructure of a large pharmaceutical company.
Keep Strategic Leadership Close to The Business
External execution does not mean externalizing accountability. Key functional leaders remain inside Cingulate, including commercial, medical, science, manufacturing, and supply-chain leadership. Those leaders work with external teams to shape and execute the strategy, keeping institutional knowledge and decision-making authority close to the company.
The model preserves the expertise that is most closely tied to the asset without requiring the company to permanently build every delivery capability. For emerging pharma, that distinction can be critical. A company may not need hundreds of employees to retain strategic control, but it does need internal leaders who understand the market, can challenge partner recommendations, and remain accountable for the quality of execution.
Build Around a Lead Partner, Not a Patchwork Of Vendors
Cingulate also chose to consolidate several commercial functions under a primary partner rather than manage a completely fragmented ecosystem. Specialist partners can still be added where they provide clear value, but the lead-partner structure reduces the coordination burden across functions such as agency work, medical affairs, market access, and field execution.
The ambition is to access "big Pharma launch capabilities" while retaining the efficiency and discipline of a smaller organization. That creates a go-to-market strategy for pharma in which orchestration becomes a core capability. The emerging company still decides what matters, but it does not have to build every system, team, and process before it can execute at national scale.
Operate as One Launch Team
The distinction between a strategic partner and a conventional vendor was a recurring theme. The organizations involved need to operate as one launch team rather than as separate groups connected by a series of handoffs. That means shared goals, clear accountability, and enough transparency for internal and external teams to make decisions together.
This is one of the harder launch challenges in pharma to solve because a distributed model can easily become fragmented. The SMART launch approach depends on orchestrating the partner ecosystem around a common plan and ensuring that functional leaders inside the company remain connected to the people doing the work. The partner relationship therefore becomes part of the operating model, not simply a sourcing decision.
Preserve Flexibility When The Plan Changes
A lighter fixed infrastructure can also provide protection when launch timelines move. Cingulate was able to respond to a regulatory delay without dismantling a large internal commercial organization. Because the company had not committed to the same level of fixed infrastructure, it had more room to adjust while keeping the launch model intact.
For an emerging company with a limited portfolio, that flexibility can be as important as the initial cost advantage. It also creates a commercialization model that can be reused across future assets rather than rebuilt from the ground up each time. The first launch therefore becomes a way to develop a repeatable capability, not simply a one-time event.
The broader takeaway is not that every emerging pharma company should follow the same structure. It is that a pharma launch strategy no longer has to begin with the assumption that strategic control requires ownership of every capability. A SMART pharma go to market model can preserve leadership, knowledge, and value while using partners to provide scale where it is needed most.